The latest price target for BioStem Technologies (OTCPK:BSEM) was reported by Zacks Investment Research on November 7, 2022. The analyst firm set a price target for $6.40 expecting BSEM to fall to within 12 months (a possible -39.05% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for BioStem Technologies (OTCPK:BSEM) was provided by Zacks Investment Research, and BioStem Technologies initiated their buy rating.

There is no last upgrade for BioStem Technologies

There is no last downgrade for BioStem Technologies.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioStem Technologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioStem Technologies was filed on November 7, 2022 so you should expect the next rating to be made available sometime around November 7, 2023.

While ratings are subjective and will change, the latest BioStem Technologies (BSEM) rating was a initiated with a price target of $0.00 to $6.40. The current price BioStem Technologies (BSEM) is trading at is $10.50, which is out of the analyst’s predicted range.